Synthesis and Preclinical Characterization of LY3154885, a Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Nonclinical Drug–Drug Interaction Risk Profile

Authors :: Junliang Hao
James Beck
Xin Zhou
Gregory L. Lackner
Richard Johnston
Matt Reinhard
Paul Goldsmith
Sean Hollinshead
Veronique Dehlinger
Sandra A. Filla
Xu-shan Wang
Jeffery Richardson
Maria Posada
Mike Mohutsky
Doug Schober
Jason S. Katner
Qi Chen
Bingjie Hu
David M. Remick
David A. Coates
Brian M. Mathes
Mai K. Hawk
Kjell A. Svensson
Erik Hembre
Source :: Journal of Medicinal Chemistry. 65:3786-3797
Publication Year :: 2022
Publisher :: American Chemical Society (ACS), 2022.
Abstract: Results from recently completed clinical studies suggest the dopamine D1 receptor positive allosteric modulator (PAM) mevidalen (

Subjects :: Neuroprotective Agents
Allosteric Regulation
Receptors, Dopamine D1
Drug Discovery
Cytochrome P-450 CYP3A
Cytochrome P-450 CYP3A Inhibitors
Humans
Molecular Medicine
Drug Interactions

Tools